Drug Trial Radar · NCT05304715
Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Apr 13, 2022
Primary completion
Jun 4, 2023
Study completion Jun 4, 2023
Sponsor
- Lead sponsor
- Hellenic Institute for the Study of SepsisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Previous data have shown that integrated information from single nucleotide polymorphisms (SNPs) of the host DNA, interleukin 8 (IL-8) and the enrichment of the stool microbiome can indicate the patients with infection by Clostridioides difficile (CDI) who are at risk for unfavorable outcome. This integrated information is forming the BEYOND score. The aim of the BEYOND randomized clinical trial (RCT) is to investigate if adjunctive bezlotoxumab treatment to the current standard-of-care may decrease the likelihood of unfavorable outcome for patients who score positive by the BEYOND score.
Conditions
- Clostridioides Difficile Infection
- Stool Microbiome
- Organ Dysfunction Syndrome
- Clostridioides Difficile Infection Recurrence
- Mortality
Interventions
BezlotoxumabDrug
Single intravenous infusion of bezlotoxumab
Normal saline 0.9% or 5% dextrose waterDrug
Single intravenous infusion - Placebo arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Superiority of Bezlotoxumab Over Placebo to Reduce the Occurence of an Unfavorable Outcome by Day 40.Time frame: 40 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis
Alexandroupoli, Greece
1st Department of Internal Medicine, THRIASIO General Hospital of Eleusis
Athens, Greece
2nd Department of Internal Medicine, Thriasio General Hospital
Athens, Greece
1st University Department of Internal Medicine, LAIKO General Hospital of Athens,
Athens, Greece
1st University Department of Propaedeutic Surgery, IPPOKRATEION General Hospital
Athens, Greece
4th Department of Internal Medicine, Attikon University Hospital
Athens, Greece
1st Department of Internal Medicine, General University Hospital of Ioannina
Ioannina, Greece
Department of Internal Medicine, Larissa University Hospital
Larissa, Greece
Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA
Pátrai, Greece
2nd Department of Internal Medicine, Tzanneion General Hospital
Piraeus, Greece
1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki
Thessaloniki, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.